Singapore 2026, How Biotech & Tech Firms Should Respond to IPOS' SG Patents Fast Suspension

On 4 January 2026, the Intellectual Property Office of Singapore (IPOS) suspended acceptance of all new requests under the SG Patents Fast and SG Trade Marks Fast acceleration programmes, removing the single fastest domestic route for obtaining an expedited patent examination in the city-state. For biotech and technology companies that have built prosecution calendars, fundraising timelines and licensing negotiations around the promise of accelerated grant, the IPOS patents suspension in Singapore demands an immediate tactical reset.

This article provides a comprehensive 2026 practitioner playbook, covering alternative acceleration routes such as the Patent Prosecution Highway (PPH), biotech-specific filing strategies, trade-secret retention frameworks and enforcement timing considerations, so that in-house counsel, IP managers, founders and R&D leads can make confident, well-informed decisions in the months ahead. Every recommendation is grounded in the official IPOS circular, the Singapore Patents Act and established international prosecution practice.

Executive Summary and Immediate Actions After the IPOS Patents Suspension in Singapore

The core facts are straightforward. IPOS has placed its acceleration programmes under review and will not accept new requests under SG Patents Fast or SG Trade Marks Fast until further notice. Requests that were received before 4 January 2026 and met the qualifying requirements at the time of submission will continue to be processed under the original programme terms. No end date for the suspension has been announced.

The practical consequence is that Singapore-based patent applicants no longer have access to a domestic fast-track examination option. For biotech firms aligning patent grant with clinical trial milestones, or technology companies seeking to enforce rights before a product launch window closes, the delay can translate into lost licensing leverage, weakened injunction postures and higher transaction risk during funding rounds.

Five-Step Urgent Checklist

• Confirm pre-suspension status. Verify whether your request was received by IPOS before 4 January 2026. If so, it should continue to be processed under SG Patents Fast terms. Request written confirmation from IPOS if your acknowledgement is unclear.
• Evaluate PPH eligibility. Determine whether you hold an allowed or granted claim set from a Patent Prosecution Highway partner office (USPTO, EPO, JPO, KIPO or others). If you do, a PPH request is the most direct alternative route to accelerate patent examination in Singapore.
• Review PCT national-phase deadlines. If your application entered the international phase, check the 30-month national-phase deadline for Singapore entry and consider whether accelerating prosecution in a foreign office first may yield a faster path to a Singapore grant.
• Assess foreign-grant acceleration options. Where a corresponding patent has already been granted abroad, explore whether reliance on that foreign prosecution history can shorten Singapore examination timelines.
• Tighten trade-secret controls now. For inventions not yet publicly disclosed, particularly pre-clinical biotech processes and proprietary algorithms, review and strengthen NDA frameworks, employment IP clauses and operational compartmentalisation immediately.

What IPOS Suspended: Timeline, Rules and the IPOS 2026 Changes

The IPOS circular, published as PT Circular 1 of 2026, confirmed that the suspension applies to both SG Patents Fast and SG Trade Marks Fast. The stated reason is that the acceleration programmes are “under review.” IPOS did not provide a projected timeline for reinstatement, nor did it indicate whether the programmes will be modified, replaced or permanently discontinued upon completion of the review.

The critical distinction for applicants is whether their request was received before 4 January 2026, not merely filed or drafted. Industry observers expect that applicants whose requests arrived on or after that date will need to pursue one of the alternative acceleration routes discussed below. For broader context on how this suspension fits within the wider landscape of protecting intellectual property across borders, applicants should consider multi-jurisdictional strategies from the outset.

Who Is Most Affected: Biotech and Technology Firms

While the IPOS patents suspension in Singapore affects all patent applicants, biotech and technology firms face disproportionate consequences because their commercial timelines are tightly coupled to patent prosecution milestones. Three representative scenarios illustrate the impact.

• Early-stage biotech seeking Series B funding. A Singapore-incorporated biotech developing a novel mRNA delivery platform had planned to present a granted Singapore patent to prospective investors during Q2 2026 due diligence. Without SG Patents Fast, the company faces a standard examination timeline that may extend well beyond the fundraising window, potentially weakening its valuation position.
• MedTech company preparing for HSA regulatory submission. A medical device firm aligned its patent grant timeline with its Health Sciences Authority (HSA) product registration schedule. The suspension disrupts this synchronisation, creating a period during which the product may reach market without enforceable patent protection in Singapore.
• SaaS platform defending against a competitor’s market entry. A technology company aware of an imminent competing product launch intended to use an accelerated Singapore patent to support a cease-and-desist strategy. Without fast-track grant, patent enforcement timing becomes uncertain, and the competitor gains additional runway.

Each scenario underscores why a considered biotech patent strategy for Singapore, one that accounts for alternative acceleration, trade-secret backstops and enforcement timing, is essential rather than optional.

Alternatives to SG Patents Fast: Step-by-Step Options to Accelerate Patent Examination in Singapore

The suspension of SG Patents Fast does not eliminate every pathway to faster patent grant. Three principal alternatives remain available, each with distinct eligibility requirements, procedural steps and expected timelines. Selecting the right route depends on where the application stands in its global prosecution lifecycle and what foreign prosecution history already exists.

Patent Prosecution Highway (PPH): How to Use It in 2026

The Patent Prosecution Highway remains the most structured alternative for applicants who already hold favourable foreign prosecution outcomes. Singapore participates in PPH arrangements with major patent offices worldwide, including the USPTO, EPO, JPO, KIPO and IP Australia, among others.

To file a PPH request with IPOS, applicants must satisfy several core requirements. First, there must be a corresponding application at the Office of Earlier Examination (OEE), that is, the foreign patent office where the claims were first examined. Second, at least one claim in that foreign application must have been determined to be allowable or patentable. Third, the claims in the Singapore application for which PPH treatment is requested must sufficiently correspond to the allowed foreign claims.

The procedural steps are as follows:

1. Identify the OEE application with the most commercially relevant allowed claim set.
2. Prepare a claims correspondence table showing how each Singapore claim maps to the allowed foreign claim.
3. Compile the required supporting documents: the OEE office action indicating allowability, any relevant search reports, and translations into English where necessary.
4. File the PPH request with IPOS, referencing the OEE determination and attaching all supporting materials.
5. Monitor for an accelerated first office action from IPOS, which typically issues faster than under standard examination, industry observers report timelines of approximately three to nine months, though actual timeframes depend on examiner workload and claim complexity.

The chief advantage of PPH is predictability: where strong foreign prosecution history exists, the Singapore examiner can rely on that analysis to expedite review. The chief limitation is that PPH is only available where claims have already been allowed abroad, meaning early-stage applications without foreign prosecution history cannot use this route.

Using Foreign Grants and Prosecution History

Even outside formal PPH arrangements, applicants with a granted patent in a major jurisdiction can leverage that prosecution history to streamline Singapore examination. Under Singapore’s patent examination framework, applicants may request that IPOS rely on the search and examination results of a corresponding application at a prescribed patent office. This mechanism, sometimes referred to as supplementary examination, allows the Singapore examiner to use the foreign grant as a substantive reference, potentially reducing the number of office actions needed to reach allowance.

The practical steps involve filing a request for examination at IPOS accompanied by the foreign grant certificate, relevant prosecution documents and a claims comparison. The likely practical effect will be a shorter examination cycle compared to a de novo Singapore examination, though not necessarily as fast as a formal PPH request. For a deeper exploration of alternatives to SG Patents Fast, practitioners should consult dedicated procedural guidance.

PCT/National-Phase Tactical Sequencing

For applications filed under the Patent Cooperation Treaty (PCT), the 30-month national-phase entry deadline for Singapore provides a strategic planning window. Rather than entering Singapore national phase immediately, applicants may benefit from accelerating prosecution in a foreign office first, obtaining an allowed claim set via USPTO Track One, EPO PACE or JPO accelerated examination, and then leveraging that result through PPH when entering Singapore.

This sequencing tactic is particularly valuable for biotech firms with multi-jurisdictional portfolios. By obtaining a foreign grant first, the applicant simultaneously satisfies regulatory filing needs in the foreign market and creates the evidentiary foundation for a PPH request in Singapore.

Biotech-Specific Filing Strategies and Timing

Biotech innovators face unique pressures that make the IPOS patents suspension in Singapore particularly consequential. Drug development timelines, clinical trial phases and regulatory approval milestones all create inflexible deadlines around which patent protection must be secured. A well-designed biotech patent strategy for Singapore must account for these realities.

Provisional Filing and R&D Disclosure Management

Filing a provisional patent application, whether in Singapore or in a priority-creating jurisdiction such as the United States, remains an effective first step for biotech inventions at an early stage. A provisional establishes a priority date and provides a 12-month window to develop the invention further, gather additional experimental data and assess commercial viability before committing to a full application. The key discipline is managing disclosure: every internal presentation, investor pitch and collaboration discussion must be evaluated for its potential to create a public disclosure that could jeopardise patentability.

PCT Timing and National Phase Tactics

A PCT application filed within the priority year extends the decision horizon to 30 months from the earliest priority date. During this period, biotech firms should pursue accelerated examination in the jurisdiction where they most urgently need protection, typically the United States or Europe, with the express goal of generating allowed claims that can anchor a PPH request upon Singapore national-phase entry. This sequencing aligns prosecution effort with clinical and commercial milestones rather than leaving grant timing to the vagaries of standard examination queues.

Claim Drafting to Preserve Enablement and Enforcement for Biotech

Biotech claims require particular care in enablement and sufficiency of disclosure. Claims that are too broad risk rejection for lack of support; claims that are too narrow may fail to cover commercially relevant variants. In the current environment, where acceleration in Singapore is no longer guaranteed, applicants should draft claims with explicit consideration of foreign-office examination standards, since those foreign allowed claims will likely form the basis for any PPH or supplementary examination request filed with IPOS.

Industry observers expect that applicants who align their Singapore claims with already-allowed foreign claims from the outset will see the most efficient prosecution outcomes. Additionally, claims should be structured to support enforcement: method-of-treatment claims, composition claims, and formulation claims each carry different enforcement implications under Singapore law, and the right combination should be informed by the anticipated infringement scenario.

Trade-Secret Strategy: Retention, Contracts and Enforcement for Trade Secret Protection in Singapore

Not every innovation should be patented. For certain categories of biotech and technology IP, particularly manufacturing processes, proprietary algorithms, pre-clinical datasets and internal know-how that cannot be readily reverse-engineered, trade-secret protection may offer superior commercial value. The IPOS suspension makes this calculus more urgent: when the patent route is slower, the relative attractiveness of trade-secret retention increases.

Contracts and Employment Provisions

The foundation of trade-secret protection in Singapore is contractual. Every employee, contractor, consultant and collaboration partner with access to confidential information should be bound by appropriately drafted agreements. Essential contractual provisions include:

Operational Controls and Documentation

Contractual provisions alone are insufficient without supporting operational measures. Best practice includes limiting access to trade-secret information on a need-to-know basis, implementing digital access controls (encrypted file systems, audit logging, role-based permissions), conducting regular training on confidentiality obligations and maintaining contemporaneous documentation of what constitutes a trade secret and why it holds commercial value. This documentation is critical: in any enforcement proceeding, the claimant must demonstrate that reasonable steps were taken to maintain secrecy.

Enforcement in Singapore: Remedies and Proof

Singapore does not have a standalone trade secrets statute. Instead, trade-secret protection arises primarily from the common law of confidence (breach of confidence) and, where contractual provisions exist, breach of contract. Remedies available to a successful claimant include injunctive relief, damages or an account of profits, and delivery up or destruction of infringing materials. The claimant must establish that the information had the necessary quality of confidence, that it was communicated in circumstances importing an obligation of confidence, and that there was unauthorised use. Early engagement with forensic IT specialists to preserve electronic evidence is essential in building a viable case.

Enforcement Timing and Litigation Practicalities After the IPOS Patents Suspension

Patent enforcement timing is directly affected by the speed at which a patent is granted. With the domestic fast-track option suspended, applicants who previously expected to hold a granted Singapore patent within six to nine months now face standard examination timelines that may extend to two years or more. This elongated window has practical consequences for injunction strategy, damages calculations and multi-jurisdictional enforcement coordination.

Where a competitor is infringing or preparing to infringe, the absence of a granted Singapore patent means that an applicant cannot commence infringement proceedings in Singapore. In such cases, firms should consider whether enforcement in a jurisdiction where the patent has already been granted, such as the United States, Europe or Japan, provides an interim mechanism to restrain the infringing activity, at least in those markets. Concurrently, all evidence of infringement in Singapore should be meticulously documented and preserved to support future proceedings once the Singapore patent is granted.

The likely practical effect of the suspension on patent enforcement timing is that firms must budget for a longer pre-grant period in Singapore and plan enforcement actions in jurisdictions where grant has already occurred. Evidence preservation, including purchasing and testing competitor products, recording public demonstrations and archiving marketing materials, should begin immediately, regardless of Singapore patent status.

Budgeting Implications and Prosecution Cost Comparison

The shift away from SG Patents Fast alters prosecution budgets. Different acceleration routes carry different cost profiles, and the trade-secret alternative involves ongoing operational expenditure rather than one-time filing fees.

For a broader overview of how IP protection strategies compare across different national systems, see our guide on how to protect your intellectual property across borders.

Practical Annex: Templates and Checklists

To support rapid implementation of the strategies outlined above, the following checklists summarise the key actions for each pathway. These are designed for use by IP managers and in-house counsel as working documents that can be adapted to specific portfolio circumstances.

• PPH evidence checklist. Compile the OEE office action with allowability determination; claims correspondence table mapping each Singapore claim to the allowed foreign claim; English translations of all foreign-language documents; search report from the OEE; and a copy of the Singapore application as filed.
• Trade-secret audit checklist. Identify and catalogue all trade secrets by category (process, data, algorithm, formulation); review and update NDA templates for employees, contractors and collaboration partners; verify digital access controls and audit logging; confirm that return-of-materials clauses are included in all engagement agreements; and schedule annual trade-secret training for all staff with access.
• Enforcement readiness checklist. Monitor competitor products and publications for potential infringement indicators; purchase and preserve competitor product samples; archive competitor marketing materials and technical documentation; engage forensic IT specialists for evidence preservation where trade-secret misappropriation is suspected; and brief litigation counsel on interim enforcement options in foreign jurisdictions.

For further context on recent regulatory changes affecting patent and trade mark applicants in Singapore, see our analysis of alternatives to SG Patents Fast. Practitioners who need jurisdiction-specific guidance can also browse the Global Law Experts Singapore lawyer directory to connect with qualified IP specialists.

Sources

1. Intellectual Property Office of Singapore (IPOS), Circular on Suspension of SG Patents Fast and SG Trade Marks Fast
2. PT Circular 1 of 2026, Official Government PDF
3. WIPO, Patent Cooperation Treaty (PCT) Overview
4. Baker McKenzie, Singapore IPOS Advisory (January 2026)
5. Allen & Gledhill, IPOS Suspension Advisory
6. Asia IP, IPOS Suspension Report
7. Singapore Statutes Online, Patents Act and Related Legislation
8. UGGC Avocats, Trade Secrets and IP Protection in Biotech